RU2480207C2 - Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы - Google Patents
Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы Download PDFInfo
- Publication number
- RU2480207C2 RU2480207C2 RU2008150489/15A RU2008150489A RU2480207C2 RU 2480207 C2 RU2480207 C2 RU 2480207C2 RU 2008150489/15 A RU2008150489/15 A RU 2008150489/15A RU 2008150489 A RU2008150489 A RU 2008150489A RU 2480207 C2 RU2480207 C2 RU 2480207C2
- Authority
- RU
- Russia
- Prior art keywords
- abacterial prostatitis
- prostatitis
- prostate
- chronic abacterial
- estrogen
- Prior art date
Links
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 28
- 230000001684 chronic effect Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 9
- 102000015694 estrogen receptors Human genes 0.000 title abstract description 3
- 108010038795 estrogen receptors Proteins 0.000 title abstract description 3
- 239000003886 aromatase inhibitor Substances 0.000 title description 7
- 229940046844 aromatase inhibitors Drugs 0.000 title description 5
- 230000004064 dysfunction Effects 0.000 claims abstract description 8
- 210000005070 sphincter Anatomy 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims abstract 2
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 claims description 6
- 229950004684 fispemifene Drugs 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003042 antagnostic effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000036732 histological change Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 16
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 13
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 13
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 11
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 11
- 239000000328 estrogen antagonist Substances 0.000 description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 9
- 230000001833 anti-estrogenic effect Effects 0.000 description 9
- 229960005309 estradiol Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 229960003604 testosterone Drugs 0.000 description 8
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 229940046836 anti-estrogen Drugs 0.000 description 5
- 238000011620 noble rat Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000000450 Pelvic Pain Diseases 0.000 description 3
- 208000013507 chronic prostatitis Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940122815 Aromatase inhibitor Drugs 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010051482 Prostatomegaly Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 102100028121 Fos-related antigen 2 Human genes 0.000 description 1
- 101001059934 Homo sapiens Fos-related antigen 2 Proteins 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960000817 bazedoxifene Drugs 0.000 description 1
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- -1 lazofoxifen Chemical compound 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003969 ospemifene Drugs 0.000 description 1
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80265706P | 2006-05-22 | 2006-05-22 | |
| US60/802,657 | 2006-05-22 | ||
| PCT/IB2007/001321 WO2007135547A2 (en) | 2006-05-22 | 2007-05-22 | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008150489A RU2008150489A (ru) | 2010-06-27 |
| RU2480207C2 true RU2480207C2 (ru) | 2013-04-27 |
Family
ID=38610674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008150489/15A RU2480207C2 (ru) | 2006-05-22 | 2007-05-22 | Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7825107B2 (enExample) |
| EP (1) | EP2029128B1 (enExample) |
| JP (1) | JP5123935B2 (enExample) |
| KR (1) | KR101505884B1 (enExample) |
| CN (1) | CN101448490A (enExample) |
| AU (1) | AU2007252991B2 (enExample) |
| BR (1) | BRPI0712103A2 (enExample) |
| CA (1) | CA2652783C (enExample) |
| ES (1) | ES2551690T3 (enExample) |
| MX (1) | MX2008014825A (enExample) |
| NO (1) | NO341185B1 (enExample) |
| RU (1) | RU2480207C2 (enExample) |
| WO (1) | WO2007135547A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| USD779449S1 (en) | 2014-10-01 | 2017-02-21 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD781275S1 (en) | 2014-10-01 | 2017-03-14 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD784972S1 (en) | 2014-10-01 | 2017-04-25 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD795855S1 (en) | 2014-10-01 | 2017-08-29 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD779450S1 (en) | 2014-10-01 | 2017-02-21 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD803818S1 (en) | 2014-10-01 | 2017-11-28 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD785586S1 (en) | 2014-10-01 | 2017-05-02 | Samsung Electronics Co., Ltd. | Portable electronic device |
| USD797713S1 (en) | 2014-10-01 | 2017-09-19 | Samsung Electronics Co., Ltd. | Portable electronic device |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2077889C1 (ru) * | 1993-02-24 | 1997-04-27 | Малое государственное предприятие "Флора" | Способ лечения хронического простатита |
| WO1998045288A1 (en) * | 1997-04-09 | 1998-10-15 | Eli Lilly And Company | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators |
| US6410043B1 (en) * | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| RU2184543C1 (ru) * | 2001-05-24 | 2002-07-10 | Московская медицинская академия им. И.М.Сеченова | Способ лечения хронического простатита |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (enExample) | 1962-09-13 | |||
| US4656187A (en) | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
| FI77839C (fi) | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
| US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| EP0260066B1 (en) | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Tamoxifen derivatives |
| US4869155A (en) * | 1988-07-11 | 1989-09-26 | The Grieve Corporation | Airflow distribution system for discharging air from a thin plenum, and oven employing same |
| US4977906A (en) | 1989-03-07 | 1990-12-18 | Scipio William J Di | Diurnal rehabilitation for incontinence trainer |
| US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
| US5219548A (en) | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
| EP0551434B1 (en) | 1990-10-01 | 1995-11-15 | The Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
| US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US5196435A (en) | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
| GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
| US5446203A (en) | 1992-08-25 | 1995-08-29 | New York University | Synthesis of haloenones and aryl or alkyl substituted enones or alkenes |
| GB2273704B (en) | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
| DE4335876A1 (de) | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
| US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5604248A (en) | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
| US5470883A (en) | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
| US5441986A (en) | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
| GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| US5658931A (en) | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
| DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| FI972235A7 (fi) | 1994-11-29 | 1997-05-27 | Hoechst Marion Roussel Inc Inc | Menetelmä triaryylietyleenijohdannaisten käyttämiseksi osteoporoosin h oidossa ja ehkäisyssä |
| US5821254A (en) | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
| GB9509572D0 (en) | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
| DE19526146A1 (de) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| EA001103B1 (ru) | 1996-01-29 | 2000-10-30 | Эли Лилли Энд Компани | Способы повышения компетенции сфинктера |
| GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
| AU4421697A (en) | 1996-09-19 | 1998-04-14 | American Home Products Corporation | Method of treating urinary incontinence |
| US5972921A (en) | 1997-12-12 | 1999-10-26 | Hormos Medical Oy Ltd. | Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men |
| GB9803521D0 (en) | 1998-02-19 | 1998-04-15 | Orion Yhtymo Oy | New compounds and pharmaceutical compositions thereof |
| US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| WO1999066915A2 (en) * | 1998-06-23 | 1999-12-29 | Southern Illinois University At Carbondale | Therapeutic applications of estrogenic carboxylic acids |
| CA2367895A1 (en) | 1999-03-17 | 2000-09-21 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
| TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| WO2002003989A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
| IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis |
| JP4301763B2 (ja) * | 2001-10-31 | 2009-07-22 | 藤倉化成株式会社 | 銀化合物ペースト |
| US20030118633A1 (en) | 2001-11-09 | 2003-06-26 | Ebrahim Versi | Combination therapy |
| US20040248989A1 (en) * | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
-
2007
- 2007-05-22 RU RU2008150489/15A patent/RU2480207C2/ru active
- 2007-05-22 AU AU2007252991A patent/AU2007252991B2/en not_active Ceased
- 2007-05-22 MX MX2008014825A patent/MX2008014825A/es active IP Right Grant
- 2007-05-22 US US11/751,846 patent/US7825107B2/en not_active Expired - Fee Related
- 2007-05-22 BR BRPI0712103-2A patent/BRPI0712103A2/pt not_active Application Discontinuation
- 2007-05-22 CN CNA2007800184357A patent/CN101448490A/zh active Pending
- 2007-05-22 JP JP2009511598A patent/JP5123935B2/ja not_active Expired - Fee Related
- 2007-05-22 ES ES07734629.4T patent/ES2551690T3/es active Active
- 2007-05-22 CA CA2652783A patent/CA2652783C/en not_active Expired - Fee Related
- 2007-05-22 WO PCT/IB2007/001321 patent/WO2007135547A2/en not_active Ceased
- 2007-05-22 EP EP07734629.4A patent/EP2029128B1/en active Active
- 2007-05-22 KR KR1020087030717A patent/KR101505884B1/ko not_active Expired - Fee Related
-
2008
- 2008-11-18 NO NO20084822A patent/NO341185B1/no not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2077889C1 (ru) * | 1993-02-24 | 1997-04-27 | Малое государственное предприятие "Флора" | Способ лечения хронического простатита |
| WO1998045288A1 (en) * | 1997-04-09 | 1998-10-15 | Eli Lilly And Company | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators |
| US6410043B1 (en) * | 1998-05-07 | 2002-06-25 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| RU2184543C1 (ru) * | 2001-05-24 | 2002-07-10 | Московская медицинская академия им. И.М.Сеченова | Способ лечения хронического простатита |
Non-Patent Citations (3)
| Title |
|---|
| DE ROSE AF et al. Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial. Urology. 2004 Jan; 63(1):13-6. US 20040248989 A1 December 9, 2004. * |
| КУШЛИНСКИЙ Н.E. и др. Рак предстательной железы. М., 2002. с.261-263. МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Новая волна, 2001, с.11. STONE NN. et al. Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions. Urol Res. 1987; 15(3): 165-7. STONE NN. et al. Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions. Urol Res. 1987; 15(3): 165-7. NASLUND MJ et al. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol. 1988 Nov; 140(5): 1049-53. BOCCARDO F, Rubagotti A, Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients. Int J Biol Markers. 2006 Apr-Jun; 21(2): 123-6. KELLOFF GJ. et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1998 Jan; 7(1): 65-7 * |
| с.3. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009537629A (ja) | 2009-10-29 |
| NO20084822L (no) | 2008-12-15 |
| CN101448490A (zh) | 2009-06-03 |
| EP2029128A2 (en) | 2009-03-04 |
| WO2007135547A2 (en) | 2007-11-29 |
| US7825107B2 (en) | 2010-11-02 |
| AU2007252991B2 (en) | 2012-08-02 |
| MX2008014825A (es) | 2008-12-01 |
| WO2007135547A3 (en) | 2008-02-07 |
| EP2029128B1 (en) | 2015-08-05 |
| CA2652783A1 (en) | 2007-11-29 |
| KR20090027640A (ko) | 2009-03-17 |
| BRPI0712103A2 (pt) | 2012-01-17 |
| KR101505884B1 (ko) | 2015-03-25 |
| JP5123935B2 (ja) | 2013-01-23 |
| CA2652783C (en) | 2015-07-14 |
| ES2551690T3 (es) | 2015-11-23 |
| US20080021111A1 (en) | 2008-01-24 |
| NO341185B1 (no) | 2017-09-04 |
| RU2008150489A (ru) | 2010-06-27 |
| AU2007252991A1 (en) | 2007-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2480207C2 (ru) | Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы | |
| US10780063B2 (en) | Method for the treatment or prevention of lower urinary tract symptoms | |
| JP6025301B2 (ja) | 治療上の使用のためのｃ−１９ステロイド | |
| US20030225118A1 (en) | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention | |
| Rasmusson et al. | Therapeutic control of androgen action | |
| Sachdeva et al. | Stroma-mediated expression of estrogen and its role in cancer |